Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
9.02
-0.88 (-8.94%)
May 9, 2025, 11:10 AM - Market open
Theravance Biopharma Revenue
Theravance Biopharma had revenue of $15.39M in the quarter ending March 31, 2025, with 6.10% growth. This brings the company's revenue in the last twelve months to $65.27M, up 6.11% year-over-year. In the year 2024, Theravance Biopharma had annual revenue of $64.38M with 12.12% growth.
Revenue (ttm)
$65.27M
Revenue Growth
+6.11%
P/S Ratio
7.46
Revenue / Employee
$672,845
Employees
97
Market Cap
450.76M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64.38M | 6.96M | 12.12% |
Dec 31, 2023 | 57.42M | 6.08M | 11.84% |
Dec 31, 2022 | 51.35M | -3.97M | -7.17% |
Dec 31, 2021 | 55.31M | -16.55M | -23.03% |
Dec 31, 2020 | 71.86M | -1.56M | -2.12% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TBPH News
- 19 hours ago - Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 11 days ago - Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress - PRNewsWire
- 15 days ago - Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 - PRNewsWire
- 4 weeks ago - Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting - PRNewsWire
- 5 weeks ago - Theravance Biopharma to Participate in an Upcoming Investor Conference - PRNewsWire
- 6 weeks ago - Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology - PRNewsWire
- 2 months ago - Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire